TY - JOUR
T1 - The AhR/P38 MAPK pathway mediates kynurenine-induced cardiomyocyte damage
T2 - The dual role of resveratrol in apoptosis and autophagy
AU - Mohiti, Sara
AU - Alizadeh, Effat
AU - Bisgaard, Line S.
AU - Ebrahimi-Mameghani, Mehrangiz
AU - Christoffersen, Christina
N1 - Publisher Copyright:
© 2025
PY - 2025
Y1 - 2025
N2 - Chronic kidney disease increases the risk of cardiovascular disease, partly due to uremic toxins, such as Kynurenine (KYN). While KYN contributes to tissue damage, its role in cardiomyocyte apoptosis and autophagy remains unclear. Resveratrol (RSV) can protect against oxidative stress and inflammation, whereas its specific effects on KYN-induced cardiomyopathy are less understood. This study aimed to investigate the role of KYN in cardiomyocyte apoptosis and autophagy and examine the protective effects of RSV against KYN-induced damage. H9C2 cardiomyocytes were cultured and treated with KYN in presence or absence of RSV or inhibitors of the AhR/Src/MAPKs pathway. Cell viability, apoptosis, mitochondrial membrane potential, and autophagy were assessed using MTT, TUNEL, JC-1, and autophagy detection assays. KYN induced apoptosis, and autophagy in H9C2 cells. RSV pretreatment reduced apoptosis but enhanced autophagy in KYN-treated cells. Inhibiting autophagy or blocking apoptosis, increased KYN-induced apoptosis and autophagy, respectively. Additionally, KYN treatment enhanced AhR activation and the phosphorylation of Src and MAPKs proteins, whereas RSV pretreatment decreased AhR activation and ERK phosphorylation. Inhibitors of p38 MAPK and JNK reduced expression of apoptotic proteins. AhR inhibition also reduced the phosphorylation of p38 MAPK and expression of apoptotic proteins while it enhanced autophagy-related protein expression in KYN treated H9C2 cells. In conclusion, our findings suggest that KYN induces cardiomyocyte apoptosis via the AhR/p38 MAPK pathway whereas RSV can protect against the KYN-induced apoptosis while promoting autophagy. Given the high cardiovascular risk in CKD patients, these findings provide in-sight into potential therapeutic strategies targeting KYN-induced cardiomyopathy.
AB - Chronic kidney disease increases the risk of cardiovascular disease, partly due to uremic toxins, such as Kynurenine (KYN). While KYN contributes to tissue damage, its role in cardiomyocyte apoptosis and autophagy remains unclear. Resveratrol (RSV) can protect against oxidative stress and inflammation, whereas its specific effects on KYN-induced cardiomyopathy are less understood. This study aimed to investigate the role of KYN in cardiomyocyte apoptosis and autophagy and examine the protective effects of RSV against KYN-induced damage. H9C2 cardiomyocytes were cultured and treated with KYN in presence or absence of RSV or inhibitors of the AhR/Src/MAPKs pathway. Cell viability, apoptosis, mitochondrial membrane potential, and autophagy were assessed using MTT, TUNEL, JC-1, and autophagy detection assays. KYN induced apoptosis, and autophagy in H9C2 cells. RSV pretreatment reduced apoptosis but enhanced autophagy in KYN-treated cells. Inhibiting autophagy or blocking apoptosis, increased KYN-induced apoptosis and autophagy, respectively. Additionally, KYN treatment enhanced AhR activation and the phosphorylation of Src and MAPKs proteins, whereas RSV pretreatment decreased AhR activation and ERK phosphorylation. Inhibitors of p38 MAPK and JNK reduced expression of apoptotic proteins. AhR inhibition also reduced the phosphorylation of p38 MAPK and expression of apoptotic proteins while it enhanced autophagy-related protein expression in KYN treated H9C2 cells. In conclusion, our findings suggest that KYN induces cardiomyocyte apoptosis via the AhR/p38 MAPK pathway whereas RSV can protect against the KYN-induced apoptosis while promoting autophagy. Given the high cardiovascular risk in CKD patients, these findings provide in-sight into potential therapeutic strategies targeting KYN-induced cardiomyopathy.
KW - Aryl hydrocarbon receptor
KW - Cardiomyocytes
KW - H9C2
KW - Kynurenine
KW - MAPKs
KW - Tryptophan
U2 - 10.1016/j.biopha.2025.118015
DO - 10.1016/j.biopha.2025.118015
M3 - Journal article
C2 - 40153993
AN - SCOPUS:105000952961
SN - 0753-3322
VL - 186
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
M1 - 118015
ER -